You're at Risk for Blood Clots. Your Genes May Explain Why.

Factor V is one of the most critical blood clotting factors in your body. It sits at the heart of the coagulation cascade, helping convert prothrombin into thrombin, which in turn converts fibrinogen into fibrin, the actual clot. When this gene works normally, clotting is tightly controlled and only happens when you actually need it.

The Factor V Leiden variant (R506Q) is carried by roughly 5 percent of people with European ancestry, and it’s a game changer. This single point mutation makes Factor V resistant to breakdown by a natural anticoagulant called activated protein C. This means clots form more easily and dissolve more slowly, increasing venous thromboembolism risk 4 to 8 times over normal. If you’re a woman taking oral contraceptives, that risk multiplies to 80 times. That’s why the F5 Leiden variant is considered one of the most important genetic risk factors for unprovoked blood clots.

You likely haven’t had symptoms yet, but if you carry F5 Leiden, your blood is literally thicker than it needs to be. Long flights, surgery, immobilization, or hormonal birth control become high-risk situations. Your leg swells more easily after sitting. Bruises linger. You might feel heavy or sluggish in your legs without knowing why.

Prothrombin (Factor II) is the precursor to thrombin, the enzyme that actually creates fibrin and forms the physical clot. It’s the central hub of the entire coagulation cascade. When Factor V activates prothrombin, thrombin is released into the bloodstream and the clotting process accelerates. Normally, this is tightly regulated and stops when the wound is sealed.

The F2 G20210A variant is found in roughly 2 to 3 percent of people with European ancestry. This polymorphism increases the amount of prothrombin your liver produces. Higher prothrombin levels mean your blood is more likely to activate the clotting cascade, increasing thrombosis risk 2 to 3 times. And the risk becomes even more significant if you also carry F5 Leiden; the two variants compound each other and push you into a much higher-risk category.

You might not feel this happening. Prothrombin levels don’t cause chest pain or leg swelling on their own. But over time, and especially during periods of immobility or with hormonal triggers, your blood becomes progressively more prone to clotting. Superficial veins may become more prominent. You may bruise more easily. Your recovery from surgery might be marked by more swelling than seems normal.

PAI1 is nature’s brake on clot breakdown. Your body is constantly forming small clots and dissolving them; it’s a normal, healthy process called fibrinolysis. PAI1 inhibits plasminogen activators, the enzymes that dissolve clots. When PAI1 is working normally, the balance is perfect: clots form when needed and dissolve when the job is done.

The PAI1 4G/5G polymorphism affects how much PAI1 your body produces. People with the 4G/4G genotype (found in roughly 25 percent of the population) produce higher levels of PAI1. Higher PAI1 means your body’s clot-dissolving enzymes are inhibited more strongly, and clots persist longer in your bloodstream. This increases thrombosis risk and is also associated with worse cardiovascular outcomes in people with previous heart attacks or strokes. The 4G allele is also linked to higher triglycerides and metabolic dysfunction.

You may notice that small cuts take longer to stop bleeding than expected, or that bruises linger longer than they should. Internally, dissolved clots accumulate longer than they should, increasing the chance they’ll migrate or grow larger. If you also carry F5 Leiden or F2 prothrombin variants, slow clot dissolution becomes a compounding problem.

MTHFR is the enzyme that converts dietary folate into a usable form called methylfolate, which your body uses to regulate homocysteine. Homocysteine is an amino acid that, when elevated, damages blood vessel walls and triggers clotting. This is why it’s called an independent cardiovascular risk factor. MTHFR is therefore absolutely critical for cardiovascular health. When it works normally, homocysteine stays low and blood vessels stay healthy.

The MTHFR C677T variant is carried by roughly 40 percent of people with European ancestry. This variant reduces MTHFR enzyme activity by 35 to 40 percent. Lower enzyme activity means your body cannot convert dietary folate efficiently, and homocysteine accumulates. Elevated homocysteine directly damages the inner lining of blood vessels (the endothelium), triggering inflammation and making the vessel walls stickier. This accelerates atherosclerosis and dramatically increases blood clotting risk. The effect compounds if you also carry F5 Leiden or F2 variants.

You may not feel elevated homocysteine directly, but you might notice that your recovery from cardiovascular events is slow, or that you seem more prone to bruising and clotting than your family history would predict. If you have migraines, foggy thinking, or mood issues alongside cardiovascular concerns, MTHFR dysfunction is a key suspect.

NOS3 encodes endothelial nitric oxide synthase, the enzyme that produces nitric oxide in your blood vessels. Nitric oxide is one of the most powerful vasodilators in your body; it relaxes smooth muscle in blood vessel walls and keeps them flexible, dilated, and flowing freely. When NOS3 works normally, your arteries and veins respond dynamically to blood flow demands, and clot formation is minimized.

The NOS3 Glu298Asp variant (rs1799983) is carried by roughly 30 to 40 percent of the population. This variant reduces nitric oxide production in the endothelium. Lower nitric oxide means your blood vessels are stiffer, less responsive, and more prone to stasis (sluggish blood flow). Sluggish blood flow is a known trigger for clot formation. This variant also increases hypertension risk and accelerates atherosclerosis, both of which further increase clotting risk. The effect is especially pronounced in people who also have F5 or F2 variants.

You might notice that your blood pressure runs higher than expected, or that your legs feel heavy and sluggish after sitting. Cold hands and feet are common. You might have slower wound healing. During long flights or periods of immobility, your legs swell more than your travel companions’ do.

VKORC1 encodes the enzyme that recycles vitamin K after it’s been used to activate clotting factors. Vitamin K is essential for the production of Factors II, VII, IX, and X, all of which are critical steps in the coagulation cascade. When VKORC1 works normally, your body maintains a steady state of vitamin K recycling and clotting factor production. This is why vitamin K is so tightly controlled: too little impairs clotting, too much accelerates it.

The VKORC1 polymorphism has two main variants: the C allele (wild-type) and the T allele (variant). People with the T allele (found in 30 to 40 percent of people with European ancestry, higher in other populations) have reduced VKORC1 enzyme activity. Lower enzyme activity means vitamin K is recycled less efficiently, clotting factors are produced at lower levels, and the blood is naturally thinner. This variant is crucial information if you’re ever prescribed warfarin (Coumadin), as VKORC1 status is one of the strongest predictors of warfarin dose requirements. People with the T allele typically need much lower warfarin doses than those with the C/C genotype.

In the absence of anticoagulation therapy, you might not feel VKORC1 variants directly. But if you’re taking warfarin, bleeding risk is significantly higher with certain genotypes. You might bruise more easily, have nosebleeds more frequently, or require constant dose adjustments to stay in the therapeutic INR window.